GSK/Shionogi Joint Venture Will Have HIV Integrase Inhibitor In Phase II
GlaxoSmithKline's HIV integrase inhibitor research will advance to the clinical stage via a joint venture agreement with the Japanese firm Shionogi.
GlaxoSmithKline's HIV integrase inhibitor research will advance to the clinical stage via a joint venture agreement with the Japanese firm Shionogi.